Immunotherapy (Issue 3) | Special Reports

The Next Wave in Immunotherapy: Combinations

August 19, 2014

Clinical Articles

Advances in our understanding of critical immunomodulatory checkpoints, such as the cytotoxic T-lymphocyte antigen 4 (CTLA-4), have led to some recent notable successes in the immunotherapy of cancer.

In Practice: Q&A on Immunotherapy in Bladder Cancer With Daniel P. Petrylak, MD

August 18, 2014

Clinical Articles

The development of new immunotherapies for cancer treatment generated significant interest at the 2014 ASCO Annual Meeting, particularly checkpoint inhibitors targeting the PD-1 receptor and its ligand, PD-L1.